Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Sarepta Therapeutics
(NQ:
SRPT
)
112.80
-0.53 (-0.47%)
Streaming Delayed Price
Updated: 11:09 AM EDT, May 29, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Sarepta Therapeutics
< Previous
1
2
3
4
5
6
7
8
9
...
13
14
Next >
Could Sarepta Therapeutics Become the Next Vertex Pharmaceuticals?
January 25, 2024
It's always tough to be compared to a giant.
Via
The Motley Fool
Sarepta Therapeutics Inc.: Why it's a rising gene therapy star
January 23, 2024
Sarepta Therapeutics Inc. (NASDAQ: SRPT) is a leading commercial-stage biotech focused on developing precision gene therapy treatments for rare diseases.
Via
MarketBeat
Why Sarepta Therapeutics Stock Zoomed Nearly 5% Higher Today
January 22, 2024
One pundit feels there is solid potential in one of the company's more recently approved drugs.
Via
The Motley Fool
Catalyst Countdown: 3 Biotech Stocks With Upcoming News That Could Move the Market
January 16, 2024
In the volatile world of biotech stocks, keeping an eye on the news is critical. Here are three companies to look out for.
Via
InvestorPlace
Sarepta Therapeutics Initiates Screening in EMERGENE, a Phase 3 Clinical Study of SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E/R4
January 16, 2024
From
Sarepta Therapeutics, Inc.
Via
Business Wire
A Closer Look at 14 Analyst Recommendations For Sarepta Therapeutics
January 10, 2024
Via
Benzinga
Sarepta Therapeutics Inc. (NASDAQ: SRPT) Making Surprising Moves in Tuesday Session
January 09, 2024
Via
Investor Brand Network
Stocks Flip To Losses, Nvidia Defies Gravity, Bitcoin Pauses For A Breather: What's Driving Markets Tuesday?
January 09, 2024
Tuesday on Wall Street was marked by a subdued trend in major equity indices as investors remained cautious ahead of key inflation data scheduled for release on Thursday and the kick-off of the...
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
Sarepta Expects Prelim Gene Therapy Revenue To Be $131M In Q4, $200M For Fiscal Year
January 09, 2024
Monday, Sarepta Therapeutics Inc (NASDAQ: SRPT) reported preliminary FY23 net product
Via
Benzinga
Bumble (BMBL) Stock Pops as Elliott Builds a Stake in Rival Match
January 09, 2024
Bumble stock is rising on Tuesday as BMBL investors learn of a $1 billion investment in rival dating services company Match.
Via
InvestorPlace
Why Is Sarepta Therapeutics (SRPT) Stock Up Today?
January 09, 2024
Sarepta Therapeutics stock is rising higher on Tuesday as SRPT investors react to positive comments from company CEO Douglas Ingram.
Via
InvestorPlace
The Latest Analyst Ratings for Sarepta Therapeutics
December 12, 2023
Via
Benzinga
Could Sarepta Therapeutics Stock Help You Become a Millionaire?
December 09, 2023
Can this struggling stock turn its fortunes around?
Via
The Motley Fool
Analyst Ratings for Sarepta Therapeutics
November 21, 2023
Via
Benzinga
Acuity Brands Posts Upbeat Earnings, Joins Accolade, Urban Outfitters And Other Big Stocks Moving Higher On Tuesday
January 09, 2024
U.S. stocks traded lower, with the Dow Jones index falling over 250 points on Tuesday.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
2 Growth Stocks That Could Make You Richer in 2024 and Beyond
January 09, 2024
Last year wasn't great for either stock, but that's no reason to ignore them.
Via
The Motley Fool
Sarepta Therapeutics Reports Preliminary* Fourth Quarter and Full-Year 2023 Net Product Revenue
January 08, 2024
From
Sarepta Therapeutics, Inc.
Via
Business Wire
5 Biotech Stocks That Should Be On Investors' Radar As JPMorgan Healthcare Conference Gets Underway Monday
January 08, 2024
The rebound by biopharma stocks in 2023 and the pickup in M&A news flow makes the 2024 JPMorgan Healthcare conference even more interesting.
Via
Benzinga
3 Top Biotech Stocks Worth Adding To Your Portfolio In 2024
January 07, 2024
Given the continuous need for innovative medical treatments, the biotech industry may be a haven despite its inherent volatility and an uncertain macroeconomic environment. Here are three top biotech...
Via
Talk Markets
Blood Cancer Player Arcellx Finds Place On Analyst Conviction List - Potential Room For Growth In 2024
January 04, 2024
Needham analyst forecasts positive outlook for Arcellx Inc (ACLX) in 2024, citing potential from pivotal interim readout & strong data from Phase I study, raising price target & adding to Conviction...
Via
Benzinga
Sarepta Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 02, 2024
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 29, 2023
From
Sarepta Therapeutics, Inc.
Via
Business Wire
3 Things About Sarepta Therapeutics Every Smart Investor Knows
December 28, 2023
Mastering this stock requires appreciating a few scientific nuances.
Via
The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
December 27, 2023
Via
Benzinga
Could Sarepta Therapeutics Be the Next Vertex Pharmaceuticals Stock?
December 22, 2023
Both develop medicines for rare diseases, and each aims to conquer a niche market.
Via
The Motley Fool
Sarepta Therapeutics Submits Efficacy Supplement to Expand the ELEVIDYS Label to include Duchenne Muscular Dystrophy Patients without Restriction to Age or Ambulatory Status
December 22, 2023
From
Sarepta Therapeutics, Inc.
Via
Business Wire
1 Revolutionary Stock That Could Make You Richer in 2024 and Beyond
December 17, 2023
Many investors are bailing out, but that might be a mistake.
Via
The Motley Fool
My Take: 4 Strong Growth Stocks to Buy This Week
December 08, 2023
These strong stocks are still available at a great price. That may not be the case a whole lot longer.
Via
The Motley Fool
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 30, 2023
From
Sarepta Therapeutics, Inc.
Via
Business Wire
ROSEN, A LEADING NATIONAL FIRM, Encourages Sarepta Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - SRPT
November 18, 2023
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
< Previous
1
2
3
4
5
6
7
8
9
...
13
14
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.